HWA
SPRO icon

Heritage Wealth Advisors’s Spero Therapeutics SPRO Stock Holding History

Heritage Wealth Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-187
Closed -$226 – 589
2023
Q3 		$226 Hold
187
– – ﹤0.01% 498
2023
Q2 		$271 Hold
187
– – ﹤0.01% 535
2023
Q1 		$271 Hold
187
– – ﹤0.01% 554
2022
Q4 		$324 Hold
187
– – ﹤0.01% 543
2022
Q3 		$374 Hold
187
– – ﹤0.01% 511
2022
Q2 		$0 Hold
187
– – ﹤0.01% 579
2022
Q1 		$2K Hold
187
– – ﹤0.01% 507
2021
Q4 		$3K Hold
187
– – ﹤0.01% 506
2021
Q3 		$3.44K Hold
187
– – ﹤0.01% 489
2021
Q2 		$2.61K Buy
+187
New +$2.61K ﹤0.01% 503

Other funds holding SPRO

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Heritage Wealth Advisors's SPRO Position: Q4 2023 in Review

Heritage Wealth Advisors sold out of Spero Therapeutics (SPRO) in Q4 2023, closing a stake of 187 shares — an estimated $226 sold.

Heritage Wealth Advisors first reported a position in SPRO in Q2 2021 and held it in 10 quarters. The position peaked at $3.44K in Q3 2021. 50 funds tracked by Wall St. Rank hold SPRO as of Q4 2023.

  • Heritage Wealth Advisors reported no remaining Spero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Heritage Wealth Advisors sold 187 Spero Therapeutics shares in Q4 2023, an estimated $226.
  • Heritage Wealth Advisors first reported a position in Spero Therapeutics in Q2 2021 and held it in 10 quarters.
  • Heritage Wealth Advisors's Spero Therapeutics position peaked at $3.44K in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2023.

Based on Heritage Wealth Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.